Edgar Filing: HEMISPHERX BIOPHARMA INC - Form 4

	-	uga i m								
HEMISPHE Form 4 June 16, 201	RX BIOPHARM	A INC								
								OMB A	PPROVA	L
FORM	UNITED	STATES	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					OMB Number:	3235-	0287
Check th if no long subject to Section 1 Form 4 c Form 5 obligatio may cont	ger 5 16. 5 5 5 5 5 5 5 5 5 5 5 5 5	IENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES suant to Section 16(a) of the Securities Exchange Act of 1934, a) of the Public Utility Holding Company Act of 1935 or Section						Estimated burden hou response	Estimated average burden hours per response 0.5	
<i>See</i> Instr 1(b).	uction	30(n)	of the fi	nvestment	. Compan	y Act of 1	940			
(Print or Type I	Responses)									
1. Name and Address of Reporting Person <u>*</u> STRAYER DAVID R			2. Issuer Name and Ticker or Trading Symbol HEMISPHERX BIOPHARMA INC [HEB]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last)	3. Date of Earliest Transaction (Month/Day/Year)			Director 10% Owner X Officer (give title Other (specify below) below)						
918 ROCK CREEK ROAD			06/15/2016			Chief Science/Medical Officer				
	4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person						
BRYN MA	WR, PA 19010						Form filed by Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Securities A	cquired, Disposed o	of, or Beneficia	lly Owned	ł
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature Indirect Beneficia Ownershi (Instr. 4)	ıl
Reminder: Rep	oort on a separate line	e for each cl	ass of sec	urities benef	ficially owr	ned directly of	or indirectly.			
					inform requir	ation cont ed to respo ys a currei	spond to the collect ained in this form ond unless the for ntly valid OMB con	are not m	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: HEMISPHERX BIOPHARMA INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)	 Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 					
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Rights (1)	\$ O	06/15/2016		А	24,203		12/15/2016	12/15/2016	Common Stock	24,203

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
STRAYER DAVID R 918 ROCK CREEK ROAD BRYN MAWR, PA 19010			Chief Science/Medical Officer					

Signatures

David R. Strayer 06/16/2016

<u>**</u>Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Issued pursuant to the Hemispherx Biopharma Inc 2016 voluntary incentive stock award plan. Pursuant to the plan, the reporting person has elected to withhold a portion of their salary in exchange for the incentive right. The incentive right grants the reporting person the

(1) right to receive a number of shares of common stock based upon the market price on the day prior to election. The incentive right automatically converts to common stock on the date exercisable. The plan is described in the Issuer's annual 10K report for the year ended 12/31/15.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.